PDL Focus Remains Nuvion, But 2007 Could Include Several Significant Deals
This article was originally published in Pharmaceutical Approvals Monthly
While PDL BioPharma hopes to advance its lead product Nuvion into a pivotal ulcerative colitis trial by mid-2007, the firm is also looking to expand its acute care portfolio through several anticipated partnerships and the acquisition of a commercial product.
You may also be interested in...
Roche/Protein Design Labs will pursue a broad moderate to severe asthma indication for Zenapax (daclizumab) in an attempt to gain an advantage over Xolair, under a co-development agreement announced Sept. 16.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011